Evidence network for deaths_(OS)

1IMpassion-130 (all population), 20181IMpassion-131 (all population), 20201KEYNOTE-355 (all population), 20201PAKT (all population), 20201LOTUS, 20171BrighTNess (velaparib-P-C (arm A) vs paclitaxel alone (arm C)), 20181TORCHLIGHT, 2024atezolizumab plus nab-paclitaxel vs. atezolizumab plus paclitaxel 0.77 [0.57; 1.04]0.77 [0.57;1.04]atezolizumab plus nab-paclitaxel vs. atezolizumab plus paclitaxel 0.77 [0.57; 1.04]atezolizumab plus nab-paclitaxel vs. capivasertib plus paclitaxel 1.41 [0.84; 2.38]1.41 [0.84;2.38]atezolizumab plus nab-paclitaxel vs. capivasertib plus paclitaxel 1.41 [0.84; 2.38]atezolizumab plus nab-paclitaxel vs. ipatasertib plus paclitaxel 1.08 [0.65; 1.77]1.08 [0.65;1.77]atezolizumab plus nab-paclitaxel vs. ipatasertib plus paclitaxel 1.08 [0.65; 1.77]atezolizumab plus nab-paclitaxel vs. pembrolizumab plus SoC 0.97 [0.76; 1.23]0.97 [0.76;1.23]atezolizumab plus nab-paclitaxel vs. pembrolizumab plus SoC 0.97 [0.76; 1.23]atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC) 0.86 [0.72; 1.02]0.86 [0.72;1.02]atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC) 0.86 [0.72; 1.02]atezolizumab plus nab-paclitaxel vs. veliparib plus paclitaxel plus carboplatin 1.05 [0.60; 1.83]1.05 [0.60;1.83]atezolizumab plus nab-paclitaxel vs. veliparib plus paclitaxel plus carboplatin 1.05 [0.60; 1.83]atezolizumab plus paclitaxel vs. atezolizumab plus nab-paclitaxel 1.30 [0.97; 1.76]1.30 [0.97;1.76]atezolizumab plus paclitaxel vs. atezolizumab plus nab-paclitaxel 1.30 [0.97; 1.76]atezolizumab plus paclitaxel vs. capivasertib plus paclitaxel capivasertib plus paclitaxel better 1.84 [1.06; 3.18]1.84 [1.06;3.18]atezolizumab plus paclitaxel vs. capivasertib plus paclitaxel capivasertib plus paclitaxel better 1.84 [1.06; 3.18]atezolizumab plus paclitaxel vs. ipatasertib plus paclitaxel 1.40 [0.82; 2.38]1.40 [0.82;2.38]atezolizumab plus paclitaxel vs. ipatasertib plus paclitaxel 1.40 [0.82; 2.38]atezolizumab plus paclitaxel vs. pembrolizumab plus SoC 1.26 [0.94; 1.68]1.26 [0.94;1.68]atezolizumab plus paclitaxel vs. pembrolizumab plus SoC 1.26 [0.94; 1.68]atezolizumab plus paclitaxel vs. Standard of Care (SoC) 1.12 [0.88; 1.43]1.12 [0.88;1.43]atezolizumab plus paclitaxel vs. Standard of Care (SoC) 1.12 [0.88; 1.43]atezolizumab plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin 1.37 [0.76; 2.44]1.37 [0.76;2.44]atezolizumab plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin 1.37 [0.76; 2.44]capivasertib plus paclitaxel vs. atezolizumab plus nab-paclitaxel 0.71 [0.42; 1.20]0.71 [0.42;1.20]capivasertib plus paclitaxel vs. atezolizumab plus nab-paclitaxel 0.71 [0.42; 1.20]capivasertib plus paclitaxel vs. atezolizumab plus paclitaxel capivasertib plus paclitaxel better 0.54 [0.31; 0.94]0.54 [0.31;0.94]capivasertib plus paclitaxel vs. atezolizumab plus paclitaxel capivasertib plus paclitaxel better 0.54 [0.31; 0.94]capivasertib plus paclitaxel vs. ipatasertib plus paclitaxel 0.76 [0.39; 1.51]0.76 [0.39;1.51]capivasertib plus paclitaxel vs. ipatasertib plus paclitaxel 0.76 [0.39; 1.51]capivasertib plus paclitaxel vs. pembrolizumab plus SoC 0.69 [0.41; 1.15]0.69 [0.41;1.15]capivasertib plus paclitaxel vs. pembrolizumab plus SoC 0.69 [0.41; 1.15]capivasertib plus paclitaxel vs. Standard of Care (SoC) capivasertib plus paclitaxel better 0.61 [0.37; 1.00]0.61 [0.37;1.00]capivasertib plus paclitaxel vs. Standard of Care (SoC) capivasertib plus paclitaxel better 0.61 [0.37; 1.00]capivasertib plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin 0.74 [0.36; 1.53]0.74 [0.36;1.53]capivasertib plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin 0.74 [0.36; 1.53]ipatasertib plus paclitaxel vs. atezolizumab plus nab-paclitaxel 0.93 [0.56; 1.54]0.93 [0.56;1.54]ipatasertib plus paclitaxel vs. atezolizumab plus nab-paclitaxel 0.93 [0.56; 1.54]ipatasertib plus paclitaxel vs. atezolizumab plus paclitaxel 0.71 [0.42; 1.21]0.71 [0.42;1.21]ipatasertib plus paclitaxel vs. atezolizumab plus paclitaxel 0.71 [0.42; 1.21]ipatasertib plus paclitaxel vs. capivasertib plus paclitaxel 1.31 [0.66; 2.59]1.31 [0.66;2.59]ipatasertib plus paclitaxel vs. capivasertib plus paclitaxel 1.31 [0.66; 2.59]ipatasertib plus paclitaxel vs. pembrolizumab plus SoC 0.90 [0.55; 1.48]0.90 [0.55;1.48]ipatasertib plus paclitaxel vs. pembrolizumab plus SoC 0.90 [0.55; 1.48]ipatasertib plus paclitaxel vs. Standard of Care (SoC) 0.80 [0.50; 1.28]0.80 [0.50;1.28]ipatasertib plus paclitaxel vs. Standard of Care (SoC) 0.80 [0.50; 1.28]ipatasertib plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin 0.98 [0.48; 1.98]0.98 [0.48;1.98]ipatasertib plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin 0.98 [0.48; 1.98]pembrolizumab plus SoC vs. atezolizumab plus nab-paclitaxel 1.03 [0.82; 1.31]1.03 [0.82;1.31]pembrolizumab plus SoC vs. atezolizumab plus nab-paclitaxel 1.03 [0.82; 1.31]pembrolizumab plus SoC vs. atezolizumab plus paclitaxel 0.79 [0.59; 1.06]0.79 [0.59;1.06]pembrolizumab plus SoC vs. atezolizumab plus paclitaxel 0.79 [0.59; 1.06]pembrolizumab plus SoC vs. capivasertib plus paclitaxel 1.46 [0.87; 2.45]1.46 [0.87;2.45]pembrolizumab plus SoC vs. capivasertib plus paclitaxel 1.46 [0.87; 2.45]pembrolizumab plus SoC vs. ipatasertib plus paclitaxel 1.11 [0.68; 1.83]1.11 [0.68;1.83]pembrolizumab plus SoC vs. ipatasertib plus paclitaxel 1.11 [0.68; 1.83]pembrolizumab plus SoC vs. Standard of Care (SoC) 0.89 [0.76; 1.05]0.89 [0.76;1.05]pembrolizumab plus SoC vs. Standard of Care (SoC) 0.89 [0.76; 1.05]pembrolizumab plus SoC vs. veliparib plus paclitaxel plus carboplatin 1.09 [0.62; 1.89]1.09 [0.62;1.89]pembrolizumab plus SoC vs. veliparib plus paclitaxel plus carboplatin 1.09 [0.62; 1.89]Standard of Care (SoC) vs. atezolizumab plus nab-paclitaxel 1.16 [0.98; 1.38]1.16 [0.98;1.38]Standard of Care (SoC) vs. atezolizumab plus nab-paclitaxel 1.16 [0.98; 1.38]Standard of Care (SoC) vs. atezolizumab plus paclitaxel 0.89 [0.70; 1.14]0.89 [0.70;1.14]Standard of Care (SoC) vs. atezolizumab plus paclitaxel 0.89 [0.70; 1.14]Standard of Care (SoC) vs. capivasertib plus paclitaxel capivasertib plus paclitaxel better 1.64 [1.00; 2.68]1.64 [1.00;2.68]Standard of Care (SoC) vs. capivasertib plus paclitaxel capivasertib plus paclitaxel better 1.64 [1.00; 2.68]Standard of Care (SoC) vs. ipatasertib plus paclitaxel 1.25 [0.78; 2.00]1.25 [0.78;2.00]Standard of Care (SoC) vs. ipatasertib plus paclitaxel 1.25 [0.78; 2.00]Standard of Care (SoC) vs. pembrolizumab plus SoC 1.12 [0.96; 1.32]1.12 [0.96;1.32]Standard of Care (SoC) vs. pembrolizumab plus SoC 1.12 [0.96; 1.32]Standard of Care (SoC) vs. veliparib plus paclitaxel plus carboplatin 1.22 [0.72; 2.07]1.22 [0.72;2.07]Standard of Care (SoC) vs. veliparib plus paclitaxel plus carboplatin 1.22 [0.72; 2.07]veliparib plus paclitaxel plus carboplatin vs. atezolizumab plus nab-paclitaxel 0.95 [0.55; 1.66]0.95 [0.55;1.66]veliparib plus paclitaxel plus carboplatin vs. atezolizumab plus nab-paclitaxel 0.95 [0.55; 1.66]veliparib plus paclitaxel plus carboplatin vs. atezolizumab plus paclitaxel 0.73 [0.41; 1.31]0.73 [0.41;1.31]veliparib plus paclitaxel plus carboplatin vs. atezolizumab plus paclitaxel 0.73 [0.41; 1.31]veliparib plus paclitaxel plus carboplatin vs. capivasertib plus paclitaxel 1.34 [0.65; 2.77]1.34 [0.65;2.77]veliparib plus paclitaxel plus carboplatin vs. capivasertib plus paclitaxel 1.34 [0.65; 2.77]veliparib plus paclitaxel plus carboplatin vs. ipatasertib plus paclitaxel 1.02 [0.51; 2.08]1.02 [0.51;2.08]veliparib plus paclitaxel plus carboplatin vs. ipatasertib plus paclitaxel 1.02 [0.51; 2.08]veliparib plus paclitaxel plus carboplatin vs. pembrolizumab plus SoC 0.92 [0.53; 1.60]0.92 [0.53;1.60]veliparib plus paclitaxel plus carboplatin vs. pembrolizumab plus SoC 0.92 [0.53; 1.60]veliparib plus paclitaxel plus carboplatin vs. Standard of Care (SoC) 0.82 [0.48; 1.39]0.82 [0.48;1.39]veliparib plus paclitaxel plus carboplatin vs. Standard of Care (SoC) 0.82 [0.48; 1.39]nab-paclitaxelpaclitaxelStandard of Care (SoC)nab-paclitaxel plus placeboatezolizumab plus nab-paclitaxelatezolizumab plus paclitaxelpembrolizumab plus SoCcapivasertib plus paclitaxelipatasertib plus paclitaxelveliparib plus paclitaxel plus carboplatinnab-paclitaxel plus toripalimabdirect evidencenetwork meta-analysis
T vs. C nab-paclitaxelpaclitaxelStandard of Care (SoC)nab-paclitaxel plus placeboatezolizumab plus nab-paclitaxelatezolizumab plus paclitaxelpembrolizumab plus SoCcapivasertib plus paclitaxelipatasertib plus paclitaxelveliparib plus paclitaxel plus carboplatinnab-paclitaxel plus toripalimab
nab-paclitaxel---NANANANANANANANANANA
paclitaxelNA---NANANANANANANANANA
Standard of Care (SoC)NANA---NA1.16
0.98; 1.38		0.89
0.70; 1.14		1.12
0.96; 1.32		1.64
1.00; 2.68		1.25
0.78; 2.00		1.22
0.72; 2.07		NA
nab-paclitaxel plus placeboNANANA---NANANANANANANA
atezolizumab plus nab-paclitaxelNANA0.86
0.72; 1.02		NA---0.77
0.57; 1.04		0.97
0.76; 1.23		1.41
0.84; 2.38		1.08
0.65; 1.77		1.05
0.60; 1.83		NA
atezolizumab plus paclitaxelNANA1.12
0.88; 1.43		NA1.30
0.97; 1.76		---1.26
0.94; 1.68		1.84
1.06; 3.18		1.40
0.82; 2.38		1.37
0.76; 2.44		NA
pembrolizumab plus SoCNANA0.89
0.76; 1.05		NA1.03
0.82; 1.31		0.79
0.59; 1.06		---1.46
0.87; 2.45		1.11
0.68; 1.83		1.09
0.62; 1.89		NA
capivasertib plus paclitaxelNANA0.61
0.37; 1.00		NA0.71
0.42; 1.20		0.54
0.31; 0.94		0.69
0.41; 1.15		---0.76
0.39; 1.51		0.74
0.36; 1.53		NA
ipatasertib plus paclitaxelNANA0.80
0.50; 1.28		NA0.93
0.56; 1.54		0.71
0.42; 1.21		0.90
0.55; 1.48		1.31
0.66; 2.59		---0.98
0.48; 1.98		NA
veliparib plus paclitaxel plus carboplatinNANA0.82
0.48; 1.39		NA0.95
0.55; 1.66		0.73
0.41; 1.31		0.92
0.53; 1.60		1.34
0.65; 2.77		1.02
0.51; 2.08		---NA
nab-paclitaxel plus toripalimabNANANANANANANANANANA---

pathologies: 60 - treatments: 1575 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons